Not a downer but GC tweeted months ago about lympro math, sparking SH hopes that a rev PR was in the near future. Also he said we would uplist from strength by Dec 31. Furthermore as that date approached he reassured SH's on numerous occassions that everything "remains on track" So it most definitely understandable that some would expect revenue PR or partner by mid February. The last conference he stated that focus was on creating shareholder value...i cant imagine he expects to build any value near term without non dilutive funding especially with all the acquisitions. Anyhow no im not selling no im not over invested and yes im allowed to discuss expectations Gerald has brought forth.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links